• Recombinant Human FGF-19: Bench Workflow

  2026-09-25

  Recombinant Human FGF-19 provides a defined, tag-free ligand for FGFR4 binding and cell-based activity experiments, with product-level activity and purity specifications to guide assay setup. It is suitable for controlled in vitro research, but product specifications alone do not establish effects in a particular metabolic, tissue, or disease model.

• Nicotinamide Riboside Chloride: Assay Design

  2026-09-25

  Nicotinamide Riboside Chloride (NIAGEN) can support experiments on NAD+ biology, but interpreting a response requires more than measuring precursor exposure. This guide builds a reproducibility-focused framework for separating NAD+ target engagement from downstream metabolic effects—and clarifies what retinal stem-cell research can and cannot establish.

• Fenofibrate and Age-Independent Liver Enlargement

  2026-09-24

  Across chemically induced, naturally aged, and senescence-accelerated mouse models, the study found that Fenofibrate produced liver enlargement and PPARα–YAP pathway responses comparable to those in adult mice. The findings suggest that aging did not abolish this hepatic response, while also highlighting the need to distinguish liver growth and pathway activation from evidence of long-term safety or clinical benefit.

• WDR36 Links Glycolysis to Human TE Differentiation

  2026-09-24

  This study uses human stem cell-derived blastoids to show that WDR36 supports trophectoderm commitment and blastoid formation, with transcriptomic and metabolomic findings linking WDR36 interference to reduced glucose metabolism. The work further identifies an interaction between WDR36 and LDHA, connecting a developmental regulator with glycolytic control while leaving important questions about embryo-level validation and mechanism for future study.

• Ferroptosis Research Beyond Single-Pathway Inhibition

  2026-09-23

  A study of H-151 reveals that ferroptosis can be suppressed through radical trapping as well as STING inhibition. For translational researchers, the finding sharpens a practical question: how can experiments distinguish pathway effects from direct control of lipid peroxidation? ML-210 provides a complementary way to probe ferroptotic cell death.

• From Carbon-Ion Ferroptosis to IL-2 Test Strategy

  2026-09-23

  A translational framework connecting carbon-ion radiotherapy, DHODH suppression, ferroptosis, macrophage polarization, and a carefully staged IL-2, human recombinant research workflow.

• IL-7, Human Recombinant in Immune Assays

  2026-09-22

  IL-7, human recombinant supports controlled studies of lymphoid-cell survival and signaling. This article connects IL-7 assay design with new mechanistic insights into SARS-CoV-2 PLpro regulation of ER proteins, while clearly separating established evidence from experimental opportunity.

• From Membrane Disruption to Immune-Enabled MRSA Research

  2026-09-22

  YZ462 illustrates how membrane biology, biofilm testing, and mechanistic validation can reshape antibacterial discovery against MRSA. This article extends that evidence into a translational research framework, positioning Recombinant Human IL-12 as a controlled host-response variable rather than an unvalidated therapeutic claim.

• When Condensates Become Translational Controls

  2026-09-21

  A mechanistic analysis of how arginine methylation, SMN valency, and FUS phase separation reshape neuronal granule biology—and how translational teams can design more disciplined reagent and assay strategies around these findings.

• DZNep for EZH2 and Chromatin-State Research

  2026-09-21

  DZNep provides a practical way to perturb EZH2-associated repression, connect H3K27me3 changes with cell fate, and test apoptosis or inflammatory endpoints. Its strongest value is as a mechanistic research reagent, not as a direct replacement for locus-specific chromatin restoration in human pluripotent stem cells.

• LY2109761: A Smad2/3 Assay Strategy for Cancer

  2026-09-20

  LY2109761 is a TGF-β receptor type I and II dual inhibitor for dissecting receptor-proximal signaling, EMT, invasion, and radiosensitivity. This article provides a pathway-aware assay strategy that connects biochemical potency with interpretable cancer and fibrosis readouts.

• Pomalidomide (CC-4047): Translational Strategy

  2026-09-19

  A model-aware framework for using Pomalidomide (CC-4047) to connect tumor microenvironment modulation, erythroid biology, and mutation-informed multiple myeloma research.

• Ceftolozane/Tazobactam: Evidence and Clinical Use

  2026-09-18

  The reference review presents ceftolozane/tazobactam as an antipseudomonal cephalosporin/β-lactamase inhibitor combination designed to address resistant gram-negative infections. Its main contribution is an integrated interpretation of antibacterial mechanism, resistance, pharmacokinetics, pharmacodynamics, clinical evidence, dosing, and safety rather than a single new experimental result.

• CLCC1 and Herpesvirus Nuclear Egress Fusion

  2026-09-18

  A bioRxiv study identifies the host protein CLCC1 as an essential factor in the membrane-fusion step of HSV-1 nuclear egress, resolving a major gap in the herpesvirus replication pathway. The findings connect viral capsid release with nuclear pore complex insertion and provide a mechanistic framework for studying host-directed antiviral strategies.

• IL-12 and the Next Wave of MRSA Translation

  2026-09-17

  YZ462 highlights how direct membrane disruption can address MRSA persistence, while Recombinant Human IL-12 offers a research framework for studying host immune context. This article separates evidence from hypothesis and outlines a translational workflow for evaluating host-directed strategies alongside antibacterial mechanisms.

8552 records 4/571 page Previous Next 12345 下5页 Last page